Caplin Point Laboratories Ltd
₹2297.10
-41.10 (1.76%)
Fri, 23 Oct 2026, 07:14 pm
Health Technology
Pharmaceuticals: Major
24.5KCaplin Point Laboratories PB Ratio
| Particulars | 2007 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 9.29 | 15.70 | 6.01 | 6.32 | 5.37 | 4.87 | 5.08 | 12.94 | 25.06 | 30.68 | 30.06 | 17.32 | 10.01 | 12.73 | 17.32 | 12.13 | 21.99 | 28.51 |
| Price to book ratio | 0.96 | 0.50 | 0.56 | 0.83 | 1.16 | 1.16 | 1.65 | 5.42 | 11.92 | 13.05 | 11.91 | 4.81 | 2.25 | 2.58 | 3.47 | 2.41 | 4.32 | 5.48 |
| Price to sales ratio | 0.36 | 0.25 | 0.23 | 0.36 | 0.43 | 0.37 | 0.58 | 1.98 | 4.95 | 7.52 | 8.28 | 4.83 | 2.55 | 2.94 | 4.11 | 3.14 | 5.99 | 7.96 |
| Price to cash flow ratio | 6.67 | 15.26 | 1.07 | 32.35 | 2.34 | 1.33 | 2.11 | 5.85 | 34.26 | 40.03 | 60.64 | 36.09 | 44.24 | 11.10 | 14.60 | 15.35 | 27.82 | 31.62 |
| Enterprise value | 16.64Cr | 13.23Cr | 5.02Cr | 16.84Cr | 22.02Cr | 14.12Cr | 58.97Cr | 311Cr | 1462Cr | 2838Cr | 4269Cr | 2836Cr | 1916Cr | 2650Cr | 4706Cr | 3945Cr | 9295Cr | 14502Cr |
| Enterprise value to EBITDA ratio | 5.30 | 6.59 | 1.60 | 6.93 | 3.57 | 1.12 | 2.87 | 8.86 | 18.31 | 24.91 | 23.57 | 13.12 | 7.90 | 8.26 | 11.96 | 9.09 | 17.19 | 22.62 |
| Debt to equity ratio | 0.49 | 0.51 | 0.36 | 0.41 | 0.33 | 0.21 | 0.11 | 0.05 | 0.02 | 0 | 0 | 0 | 0.04 | 0.02 | 0 | 0 | 0 | 0 |
| Return on equity % | 0 | 0 | 9.78 | 13.52 | 23.05 | 25.57 | 36.46 | 49.29 | 64.23 | 54.19 | 49.25 | 35.43 | 27.20 | 22.71 | 22.46 | 22.37 | 21.79 | 20.76 |
Caplin Point Laboratories Ltd Price to Book Ratio
The Caplin Point Laboratories Ltd Price to Book Ratio is a key financial metric used by investors to evaluate Caplin Point Laboratories Ltd's valuation, profitability, and overall financial performance. Tracking the Caplin Point Laboratories Ltd Price to Book Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Caplin Point Laboratories Ltd (NSE: CAPLIPOINT, BSE: 524742) is currently trading at ₹2297.10, with a market capitalization of ₹17940.66Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Caplin Point Laboratories Ltd Price to Book Ratio is essential for fundamental analysis.
Caplin Point Laboratories Ltd Price to Book Ratio Current Value
The current Caplin Point Laboratories Ltd Price to Book Ratio stands at 5.48.
The latest Caplin Point Laboratories Ltd Price to Book Ratio has increased compared to the previous period, indicating rising valuation or improved investor sentiment.
Caplin Point Laboratories Ltd Price to Book Ratio Historical Trend
The Caplin Point Laboratories Ltd Price to Book Ratio has shown the following historical trend:
- 2025: 5.48
- 2024: 4.32
- 2023: 2.41
- 2022: 3.47
- 2021: 2.58
The recent rise in Caplin Point Laboratories Ltd Price to Book Ratio suggests strengthening valuation trends and improving market sentiment.
What Caplin Point Laboratories Ltd Price to Book Ratio Indicates for Investors
The Caplin Point Laboratories Ltd Price to Book Ratio plays a crucial role in understanding the company's financial health and valuation.
The P/B ratio shows how the market values company assets relative to book value.
Caplin Point Laboratories Ltd Price to Book Ratio Analysis Summary
The Caplin Point Laboratories Ltd Price to Book Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Caplin Point Laboratories Ltd Price to Book Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Caplin Point Laboratories Ltd Price to Book Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.
